Hyaluronic acid market Forecast to 2027

Increasing use of hyaluronic acid in cosmetic and personal care products, as well as an increase in the number of cosmetic surgeries. Hyaluronic acid is well known for its skin benefits such as reducing the appearance of fine lines, wrinkles, redness, and dermatitis. Hyaluronic acid aids in the retention of over 1,000 times its weight in water within skin cells, making it an excellent moisturiser. It promotes skin hydration and collagen production, combats free radicals, and maintains skin elasticity. It also functions as a humectant, a hygroscopic skincare ingredient that draws moisture from its surroundings. With consumer demand for anti-aging and multifunctional personal care products increasing, personal care product manufacturers are incorporating multi-functional and multiple ingredients into their products.

Segment Overview

The hyaluronic acid market is segmented based on grades, applications, end-users, and regions. The cosmetic grade segment accounted for the majority of the market revenue in 2021, due to its high demand as a cosmetic ingredient in personal care products. On the other hand, the pharmaceutical grade segment is the fastest-growing due to its use in treating various diseases and as a biomaterial. In terms of applications, the aesthetics segment dominated the market in 2021 due to consumer demand for minimally invasive cosmetic procedures. In terms of end-users, dermatology clinics held the largest market share in 2021 due to the use of hyaluronic acid-based fillers in skin treatments. North America had the largest market share in 2021, due to the presence of a large aging population and the growing demand for minimally invasive cosmetic surgeries.

Regional Analysis

Europe has the second-largest market share for hyaluronic acid due to rising aesthetic consciousness, rapid technological advancements, and shorter procedure times, among other factors driving the market in Europe. Furthermore, the German hyaluronic acid market held the largest market share, while the UK hyaluronic acid market was the fastest growing in the European region.

In the coming years, it is expected that the market for hyaluronic acid in the Asia-Pacific region will grow rapidly due to several factors such as growing unmet medical needs in developing economies, heightened knowledge of non-invasive procedures, and rising disposable income. Among the countries in the region, the China hyaluronic acid market currently holds the largest share, while the India hyaluronic acid market is growing at a rapid pace.

Major Players

Hyaluronic acid market is mainly dominated by Genzyme Corporation (US), Zimmer Biomet (US), Seikagaku Corporation (Japan), Hoffmann-La Roche Ag (Switzerland), Allergan (Ireland), Anika Therapeutics, Salix Pharmaceuticals (US), Sanofi (France), Inc. (US),Galderma Laboratories L.P. (US), and Smith & Nephew Plc (UK).

COVID 19 Impacts

The Covid-19 pandemic has had a significant impact on the global Hyaluronic Acid market. The initial spread of the virus caused many countries to impose lockdowns and restrictions on non-essential procedures, resulting in a slowdown in the demand for Hyaluronic Acid. This was particularly true in the cosmetic and aesthetic industry, where the use of Hyaluronic Acid is common. The halt of routine medical procedures and decreased consumer spending also contributed to a decrease in demand for Hyaluronic Acid.

However, as the pandemic has continued, the market has seen a gradual recovery as countries have started to lift restrictions and return to normal operations. In addition, the increased awareness of personal health and hygiene, as well as the need for medical procedures to treat the long-term effects of the virus, has led to a resurgence in demand for Hyaluronic Acid.

Product Code: MRFR/HC/5965-CR

LIST OF CONTENTS

1 EXECUTIVE SUMMARY 16

2 MARKET INTRODUCTION 18

2.1 SCOPE OF THE STUDY 18
2.2 RESEARCH OBJECTIVE 18
2.3 MARKET STRUCTURE 18
2.4 ASSUMPTIONS & LIMITATIONS 19

3 RESEARCH METHODOLOGY 20

3.1 DATA MINING 20
3.2 SECONDARY RESEARCH 21
3.3 PRIMARY RESEARCH 22
3.4 BREAKDOWN OF PRIMARY RESPONDENTS 23
3.5 FORECASTING TECHNIQUES 24
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 25
- 3.6.1 BOTTOM-UP APPROACH 26
- 3.6.2 TOP-DOWN APPROACH 26
3.7 DATA TRIANGULATION 27
3.8 VALIDATION 27

4 MARKET DYNAMICS 28

4.1 INTRODUCTION 28
4.2 DRIVERS 29
- 4.2.1 INCREASING APPLICATION OF HYALURONIC ACID IN COSMETIC & PERSONAL CARE PRODUCTS 29
- 4.2.2 INCREASING NUMBER OF COSMETIC SURGERIES 31
- 4.2.3 EXTENSIVE USE OF HYALURONIC ACID IN THE TREATMENT OF OSTEOARTHRITIS AND DRY EYE 32
4.3 RESTRAINTS 33
- 4.3.1 AVAILABILITY OF SUBSTITUTES 33
4.4 OPPORTUNITY 34
- 4.4.1 EXTENSIVE R&D ASSOCIATED WITH HYALURONIC ACID 34
4.5 TREND 35
- 4.5.1 USE OF HYALURONIC ACID AS AN ANIMAL SUPPLEMENT 35

5 MARKET FACTOR ANALYSIS 36

5.1 SUPPLY CHAIN ANALYSIS 36
- 5.1.1 RAW MATERIAL SUPPLIERS 37
- 5.1.2 HYALURONIC ACID PRODUCERS 37
- 5.1.3 DISTRIBUTION & SALES CHANNEL 37
- 5.1.4 END USERS 38
5.2 PORTER'S FIVE FORCES MODEL 38
- 5.2.1 BARGAINING POWER OF SUPPLIERS 39
- 5.2.2 BARGAINING POWER OF BUYERS 39
- 5.2.3 THREAT OF NEW ENTRANTS 39
- 5.2.4 THREAT OF SUBSTITUTES 39
- 5.2.5 INTENSITY OF RIVALRY 39
5.3 COVID-19 IMPACT ANALYSIS 40
- 5.3.1 IMPACT ON GROWTH RATE 40
- 5.3.2 IMPACT ON MAJOR PLAYERS 40
- 5.3.3 IMPACT ON PREFERENCE OF CUSTOMERS 40
- 5.3.4 IMPACT ON AESTHETIC INDUSTRY 42

6 GLOBAL HYALURONIC ACID MARKET, BY GRADE 43

6.1 OVERVIEW 43
6.2 COSMETIC GRADE 45
6.3 PHARMACEUTICAL GRADE 46
6.4 FOOD GRADE 47

7 GLOBAL HYALURONIC ACID MARKET, BY APPLICATION 48

7.1 OVERVIEW 48
7.2 AESTHETICS 49
7.3 OSTEOARTHRITIS 50
7.4 PHARMACEUTICAL API 51
7.5 COSMETICS 52
7.6 DIETARY SUPPLEMENTS 53
7.7 OPHTHALMOLOGY 54
7.8 OTHERS 54

8 GLOBAL HYALURONIC ACID MARKET, BY END USER 56

8.1 OVERVIEW 56
8.2 PHARMACEUTICAL INDUSTRY 58
8.3 DERMATOLOGY CLINICS & COSMETIC SURGERY CENTERS 59
8.4 FOOD INDUSTRY 60
8.5 PERSONAL CARE 61
8.6 OTHERS 61

9 GLOBAL HYALURONIC ACID MARKET, BY REGION 63

9.1 OVERVIEW 63
9.2 NORTH AMERICA 65
- 9.2.1 US 67
- 9.2.2 CANADA 69
9.3 EUROPE 71
- 9.3.1 FRANCE 74
- 9.3.2 GERMANY 75
- 9.3.3 UK 77
- 9.3.4 SPAIN 78
- 9.3.5 ITALY 80
- 9.3.6 RUSSIA 81
- 9.3.7 BELGIUM 83
- 9.3.8 POLAND 84
- 9.3.9 REST OF EUROPE 86
9.4 ASIA-PACIFIC 88
- 9.4.1 CHINA 91
- 9.4.2 JAPAN 92
- 9.4.3 INDIA 94
- 9.4.4 SOUTH KOREA 95
- 9.4.5 AUSTRALIA 97
- 9.4.6 THAILAND 98
- 9.4.7 INDONESIA 100
- 9.4.8 REST OF ASIA-PACIFIC 101
9.5 LATIN AMERICA 103
- 9.5.1 BRAZIL 105
- 9.5.2 MEXICO 107
- 9.5.3 ARGENTINA 108
- 9.5.4 REST OF LATIN AMERICA 110
9.6 MIDDLE EAST & AFRICA 112
- 9.6.1 SAUDI ARABIA 115
- 9.6.2 UAE 116
- 9.6.3 TURKEY 118
- 9.6.4 SOUTH AFRICA 119
- 9.6.5 ISRAEL 121
- 9.6.6 REST OF THE MIDDLE EAST &AFRICA 122

10 COMPETITIVE LANDSCAPE 124

10.1 OVERVIEW 124
10.2 COMPETITIVE BENCHMARKING 125
10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL HYALURONIC ACID MARKET 127
10.4 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 128
10.5 KEY DEVELOPMENTS & GROWTH STRATEGIES 129
- 10.5.1 JOINT VENTURES & AGREEMENTS 130
- 10.5.2 MARKETING STRATEGY 130
- 10.5.3 MERGERS&ACQUISITIONS 130
10.6 FINANCIAL MATRIX 131

11 COMPANY PROFILES 132

11.1 ALLERGAN PLC 132
- 11.1.1 COMPANY OVERVIEW 132
- 11.1.2 FINANCIAL OVERVIEW 133
- 11.1.3 PRODUCTS/SERVICES OFFERED 133
- 11.1.4 KEY DEVELOPMENTS 134
- 11.1.5 SWOT ANALYSIS 134
- 11.1.6 KEY STRATEGIES 135
11.2 CONTIPRO AS. 136
- 11.2.1 COMPANY OVERVIEW 136
- 11.2.2 FINANCIAL OVERVIEW 136
- 11.2.3 PRODUCTS OFFERED 136
- 11.2.4 KEY DEVELOPMENTS 137
- 11.2.5 SWOT ANALYSIS 137
- 11.2.6 KEY STRATEGIES 137
11.3 SYMATESE 138
- 11.3.1 COMPANY OVERVIEW 138
- 11.3.2 FINANCIAL OVERVIEW 138
- 11.3.3 PRODUCTS OFFERED 138
- 11.3.4 KEY DEVELOPMENTS 138
- 11.3.5 SWOT ANALYSIS 139
- 11.3.6 KEY STRATEGIES 139
11.4 ZHONGLAN INDUSTRY CO., LTD. 140
- 11.4.1 COMPANY OVERVIEW 140
- 11.4.2 FINANCIAL OVERVIEW 140
- 11.4.3 PRODUCTS OFFERED 140
- 11.4.4 KEY DEVELOPMENTS 140
- 11.4.5 SWOT ANALYSIS 141
- 11.4.6 KEY STRATEGIES 141
11.5 ALTERGON ITALIA SRL 142
- 11.5.1 COMPANY OVERVIEW 142
- 11.5.2 FINANCIAL OVERVIEW 142
- 11.5.3 PRODUCTS OFFERED 142
- 11.5.4 KEY DEVELOPMENTS 142
- 11.5.5 SWOT ANALYSIS 143
- 11.5.6 KEY STRATEGIES 143
11.6 FIDIA FARMACEUTICI S.P.A. 144
- 11.6.1 COMPANY OVERVIEW 144
- 11.6.2 FINANCIAL OVERVIEW 144
- 11.6.3 PRODUCTS OFFERED 144
- 11.6.4 KEY DEVELOPMENTS 144
- 11.6.5 SWOT ANALYSIS 145
- 11.6.6 KEY STRATEGIES 145
11.7 BIOIBERICA SAU. 146
- 11.7.1 COMPANY OVERVIEW 146
- 11.7.2 FINANCIAL OVERVIEW 146
- 11.7.3 PRODUCTS OFFERED 146
- 11.7.4 KEY DEVELOPMENTS 146
- 11.7.5 SWOT ANALYSIS 147
- 11.7.6 KEY STRATEGIES 147
11.8 KEWPIE CORPORATION 148
- 11.8.1 COMPANY OVERVIEW 148
- 11.8.2 FINANCIAL OVERVIEW 148
- 11.8.3 PRODUCTS OFFERED 149
- 11.8.4 KEY DEVELOPMENTS 149
- 11.8.5 SWOT ANALYSIS 150
- 11.8.6 KEY STRATEGIES 150
11.9 SEIKAGAKU CORPORATION 151
- 11.9.1 COMPANY OVERVIEW 151
- 11.9.2 FINANCIAL OVERVIEW 152
- 11.9.3 PRODUCTS OFFERED 153
- 11.9.4 KEY DEVELOPMENTS 153
- 11.9.5 SWOT ANALYSIS 154
- 11.9.6 KEY STRATEGIES 154
11.10 ANIKA THERAPEUTICS 155
- 11.10.1 COMPANY OVERVIEW 155
- 11.10.2 FINANCIAL OVERVIEW 156
- 11.10.3 PRODUCTS/SERVICES OFFERED 157
- 11.10.4 KEY DEVELOPMENTS 157
- 11.10.5 SWOT ANALYSIS 158
- 11.10.6 KEY STRATEGIES 158

12 APPENDIX 159

12.1 REFERENCES 159
12.2 RELATED REPORTS 160